B. Riley upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Neutral with a price target of $30, up from $25.  Analyst Mayank Mamtani sees a "catalyst rich" 1H of 2022 for the Company.
Full Story >>
Vote
+34